The Differences in the Safety and Tolerability of Immune Checkpoint Inhibitors as Treatment for Non-Small Cell Lung Cancer and Melanoma: Network Meta-Analysis and Systematic Review
Background: Immune checkpoint inhibitors (ICIs) have evolved for the treatment of solid tumors. In addition to the efficacy of ICIs for cancer, the adverse events (AEs) of ICIs are also noteworthy for gradually more extensive clinical use.Objective: To conduct a systematic review and network meta-an...
Saved in:
Main Authors: | Qing-Qing Chai (Author), Jiang-Yang Du (Author), Jun Zhu (Author), Bin Wu (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2019-10-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Immune Checkpoint Inhibitors in Melanoma: Review and Update
by: Eugénia Matos Pires, et al.
Published: (2018) -
Efficacy and safety of immune checkpoint inhibitors and targeted therapies in resected melanoma: a systematic review and network meta-analysis
by: Feng Sheng, et al.
Published: (2023) -
Loss of MHC-I antigen presentation correlated with immune checkpoint blockade tolerance in MAPK inhibitor-resistant melanoma
by: Jing Yu, et al.
Published: (2022) -
Efficacy of immune checkpoint inhibitors in different types of melanoma
by: Ernesto Rossi, et al.
Published: (2021) -
Role of Neoadjuvant Immune Checkpoint Inhibitors in Resectable Non-Small Cell Lung Cancer
by: Ivy Riano, et al.
Published: (2023)